ISIS 2922 antisense oligonucleotide directed against cytomegalovirus data

The Carlsbad, Calif., company reported on additional patients enrolled in its Phase I/II trial, showing that two-thirds of the 19 eyes treated (16 patients) responded with control of the infection for four to 26 weeks so far.

The mid-range dose tested was 300 ug injected weekly for four weeks and then every two weeks. A Phase II/III trial, which should start in the fourth quarter, probably will use this dose, but every other week. ...